Starling Oncology (STLN) Stock Price, News & Analysis
Ticker history: TOI became STLN (Starling Oncology, Inc.) on . Earlier news and filings retain their original names and dates. View TOI history.
Why is STLN Stock Down Today?
AI-generated explanation by Rhea-AI, written on at . How Rhea-AI works. Not financial advice.
What Changed
Price Move History
- Daily moves over 5%
- 62 252 sessions, November 5, 2025 to November 5, 2026
- Largest daily move
- +28.9% close of November 14, 2025
- 1-year change
- +63.8% closing prices, November 5, 2025 to November 5, 2026
- 1-month change
- +6.3% closing prices, October 5, 2026 to November 5, 2026
Company Description
Starling Oncology (NASDAQ: STLN) is classified in the medical care facilities industry within the Healthcare sector and carries a market capitalization of $595.2M.
STLN has gained 63.8% over the past year. The last closing price was $6.70.
For FY2025, Starling Oncology reported revenue of $502.7M with net income of -$60.6M and diluted earnings per share of -$0.54. The company operates at a net profit margin of -12.1%.
This page collects what Stock Titan holds for STLN, including price data, latest news, SEC filings, insider trading activity, financial highlights, upcoming events, and short interest trends.
Stock Performance
Starling Oncology (STLN) closed at $6.70 on November 5, 2026. Over the past 12 months, the price has gained 63.8%.
STLN Metrics & Rankings
Price returns through November 5, 2026. Month and year figures include the first trading day. Ranking links may use different dates.
Latest News
Starling Oncology has 6 recent news articles, with the latest published today. Of the recent coverage, 2 articles coincided with positive price movement and 3 with negative movement. Key topics include earnings, conferences, earnings date. View all STLN news →
SEC Filings
Starling Oncology has filed 5 recent SEC filings, including 3 Form 8-K, 1 Form 4, 1 Form 144. The most recent filing was submitted on . SEC filings provide transparency into a company's financial condition, material events, and regulatory compliance. View all STLN SEC filings →
Insider Radar
| Security | Bought | Sold |
|---|---|---|
| Common shares | 12,000 $78,480 | 298,853 $1,946,310 |
| Options | 0 | 100 $624 |
Insider selling at Starling Oncology over the past 90 days can reflect routine portfolio management, scheduled trading plans (Rule 10b5-1), tax planning, or compensation-related dispositions rather than a directional view on the stock.
Financial Highlights
Starling Oncology generated $502.7M in revenue in FY2025, operating income reached -$36.1M (-7.2% operating margin), and net income was -$60.6M, reflecting a -12.1% net profit margin. Diluted earnings per share stood at -$0.54. The company generated -$24.6M in operating cash flow. The current ratio was 1.59, measuring current assets divided by current liabilities.
Upcoming Events
Q3 2026 earnings call
APG Fall Presentation
Telephone replay end
Starling Oncology has 3 upcoming scheduled events. The next event, "Q3 2026 earnings call", is scheduled for November 5, 2026 (today). 2 of them are earnings releases or calls. Investors can track these dates to stay informed about potential catalysts that may affect the STLN stock price.
Short Interest History
Short interest in Starling Oncology (STLN) currently stands at 6.5 million shares, down 3.8% from the previous reporting period, representing 7.8% of the float.
Days to Cover History
Days to cover for Starling Oncology (STLN) currently stands at 5.6 days, up 30.4% from the previous period. The ratio is the reported short interest divided by the average daily trading volume. Since August 2026, the figure has increased by 60.1%. Across the settlements charted above, it has ranged from 3.5 to 7.3 days.
STLN Company Profile & Sector Positioning
Starling Oncology (STLN) operates in the Medical Care Facilities industry within the broader Healthcare sector and is listed on the NASDAQ.
Investors comparing STLN often look at related companies in the same sector, including GMR Solutions Inc. (GMRS), Strata Critical Medical, Inc. (SRTA), US Physical Therapy Inc (USPH), Nutex Health Inc. (NUTX), and InnovAge Holding Corp. (INNV). Comparing financial metrics, valuation ratios, and stock performance across these peers can help investors evaluate STLN's relative position within its industry.
Starling Oncology (STLN) reported third-quarter revenue growth and positive adjusted EBITDA, while narrowing its full-year revenue and free-cash-flow guidance ranges.